Loading...
•
Jun 30
•/
Nyxoah SA Q2 2025 Earnings Report
Nyxoah SA reported Q2 2025 results highlighted by FDA approval of its Genio system and strong revenue growth.
Key Takeaways
Nyxoah posted €1.34 million in revenue for Q2 2025, a 74% increase YoY, following the FDA approval of its Genio system and the beginning of its U.S. commercial launch. The company reported a net loss of €20.6 million, driven by increased commercialization and R&D investments.
Revenue rose 74% YoY to €1.34 million driven by early Genio system sales.
Gross margin remained strong at 63.4%.
Net loss widened to €20.6 million due to ramp-up in U.S. commercial launch activities.
Cash and financial assets declined to €43 million from €63 million in Q1.
Nyxoah SA
Nyxoah SA
Nyxoah SA Revenue by Segment
Revenue by Segment
Genio System Sales Revenue
CapyFin.com Forward Guidance
Nyxoah expects transformational growth ahead with the U.S. commercial rollout of the Genio system now underway.
Positive Outlook
- First and only bilateral hypoglossal neurostimulation system approved in the U.S.
- Strong DREAM trial data supports efficacy across sleep positions.
- Commercial infrastructure in place for U.S. launch.
- CE Mark expansion allows access to CCC patients in Europe.
- Access to €27.5 million in undrawn term debt for strategic flexibility.
Challenges Ahead
- Operating losses expected to continue amid commercial scale-up.
- Cash burn intensified with €20M+ net loss in Q2.
- R&D and SG&A expenses significantly increased YoY.
- Currency and macroeconomic pressures could impact European operations.
- Regulatory milestones still required for broader global expansion.